Table 1.
Patient demographics and baseline characteristics (full analysis set)
| Keverprazan (n = 180) | Lansoprazole (n = 178) | P Value | |
| Age (yr) | 44.2 ± 12.4 | 44.4 ± 11.8 | 0.9046 |
| Male sex (n) | 111 (61.7) | 108 (60.7) | 0.8472 |
| Height (cm) | 165.5 ± 8.5 | 165.2 ± 8.9 | 0.7144 |
| Weight (kg) | 64.9 ± 11.6 | 63.0 ± 11.1 | 0.1104 |
| Maximum diameter of ulcers (cm) | 0.8 ± 0.3 | 0.8 ± 0.3 | 0.8906 |
| Stage of ulcers (n) | |||
| A1 | 110 (61.1) | 108 (60.7) | 0.9929 |
| A2 | 32 (17.8) | 33 (18.5) | |
| A1 and A1 | 29 (16.1) | 27 (15.2) | |
| A1 and A2 | 1 (0.6) | 0 (0.00) | |
| A1 and H2 | 0 (0.00) | 1 (0.6) | |
| A2 and A2 | 7 (3.9) | 8 (4.5) | |
| A2 and H1 | 1 (0.6) | 1 (0.6) | |
| Helicobacter pylori positive (n) | 151 (83.9) | 153 (86.0) | 0.5850 |
| Serum gastrin (pg/mL) | 42.4 ± 32.6 | 41.6 ± 29.7 | 0.8053 |
| CYP2C19 genotypes (n)a | |||
| Slow metabolizer | 22 (12.4) | 21 (12.1) | 0.7795 |
| Intermediate metabolizer | 76 (42.7) | 79 (45.4) | |
| Normal metabolizer | 78 (43.8) | 70 (40.2) | |
| Fast metabolizer | 2 (1.1) | 4 (2.3) |
Data are represented as mean ± standardized deviation or number of subjects with percentages in parentheses.
a
Data were missing in 2 and 4 patients for the keverprazan and lansoprazole group, respectively.